Pfizer
Business & Industry
- Pfizer files lawsuit against Metsera and its directors and Novo Nordisk for breach of merger agreement
- Pfizer receives early clearance from U.S. Federal Trade Commission for Metsera acquisition
- Pfizer addresses proposal for Metsera
- Bayer's Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Research & Development
- New switch for programmed cell death identified
- AI-driven nanomedicine breakthrough paves way for personalized breast cancer therapy
- Making cancer vaccines more personal
- Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer
- Bias can lead to better therapies
- Epigenetic reprogramming safely modifies multiple genes in T Cells simultaneously for CAR-T therapies
- Study helps to understand the role of genetics in the body weight
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy